Media.Player

Enhanced Expression of TRP Channels in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Detailed Technology Description

The inventors have found that a single nucleotide polymorphism (SNP) in the promoter region of the TRPC6 gene has a higher allele frequency in IPAH patients. This SNP makes the TRPC6 gene susceptible to NF-kappa B. Additionally, it is known that NF-kappa B is activated by inflammation and hypoxia in the lung. This invention teaches that the identified SNP can be used to develop non-invasive tools to predict the diagnosis of IPAH and, further, to develop therapeutic approaches to treat the disease by targeting NF-kappa B-mediated TRPC6 transcription.

Supplementary Information

Patent Number: US7964573B2
Application Number: US2007814038A
Inventor: Remillard, Carmelle | Rubin, Lewis J. | Yu, Ying | Yuan, Jason X.-J.
Priority Date: 14 Jan 2005
Priority Number: US7964573B2
Application Date: 9 Oct 2007
Publication Date: 21 Jun 2011
IPC Current: A01N004304 | A61K003170 | A61K003800 | A61K003900 | A61K003938
US Class: 514044A | 514044 | 4241841 | 5140016 | 514002
Assignee Applicant: The Regents of the University of California
Title: Regulating expression of transient receptor potential channel genes
Usefulness: Regulating expression of transient receptor potential channel genes
Summary: The methods and compositions are useful for predicting a mammalian subject's susceptibility to IPAH, for screening for IPAH in a mammalian subject, and for preventing, diagnosing, and treating IPAH (claimed).
Novelty: Predicting a subject's susceptibility to idiopathic pulmonary arterial hypertension comprises detecting a single nucleotide polymorphism in a sample comprising a TRPC6 gene

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

7964573

Others

Intellectual Property Info

This technology is patented (#7,964,573; U.S. patent application, published 22-May-2008). Patent claims include a method of treating IPAH in a subject, the method comprising: (a) determining if the subject has a C-254G TRPC6 SNP comprising a G in position – 254 and (b) administering to the subject a therapeutically effective amount of a compound that reduces a biological activity of TRPC6, if the subject has the SNP.

Related Materials

Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13861-6. Epub 2004 Sep 9. PMID: 15358862

Tech ID/UC Case

19642/2005-073-0

Related Cases

2005-073-0

*Abstract

Transient receptor potential (TRP) genes code for a family of cation channels in several cell types, including pulmonary artery smooth muscle cells (PASMC). The inventors previously found that two specific isoforms of TRP are significantly upregulated in the PASMC of patients with idiopathic pulmonary arterial hypertension (IPAH) in comparison to normal subjects and patients with hypertension, which is secondary to other cardiopulmonary diseases. Inhibition of TRP expression by siRNA inhibits the growth of PASMC.

*IP Issue Date

Jun 21, 2011

*Principal Investigator

Name: Ivana Fantozzi

Department:

Name: Naomi Kunichika

Department:

Name: Judd Landsberg

Department:

Name: Oleksandr Platoshyn

Department:

Name: Carmelle Remillard

Department:

Name: Lewis Rubin

Department:

Name: Patricia Thistlethwaite

Department:

Name: Donna Tigno

Department:

Name: Ying Yu

Department:

Name: Jason Yuan

Department:

Country/Region

USA